Kaul D, Singh J
Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Cancer Lett. 1997 Jan 30;112(2):199-202. doi: 10.1016/s0304-3835(96)04570-3.
We have developed a polyclonal monospecific antibody (designated Ab-Ck) which recognises specifically a novel cell surface Receptor-'Ck', having inherent ability to regulate mevalonate pathway that is vital for many cellular functions ranging from growth control to differentiation. By using this 'Ab-Ck' as a probe, the Western blot analysis of protein fractions derived from various types of normal and cancerous cells/tissues revealed not only that this Receptor-'Ck' was ubiquitously present in various human organs, especially adrenal cortex, aorta, liver and brain, but also that leukaemic cell lines as well as lymphocytes from CML patients were specifically and selectively deficient in this receptor. Based upon these observations, we propose that leukaemic process may be initiated as a consequence of the deficiency of this novel Receptor-'Ck'.
我们已经研发出一种多克隆单特异性抗体（命名为Ab-Ck），它能特异性识别一种新型细胞表面受体——“Ck”，该受体具有调节甲羟戊酸途径的内在能力，而甲羟戊酸途径对从生长控制到分化等许多细胞功能至关重要。通过使用这种“Ab-Ck”作为探针，对来自各种正常和癌细胞/组织的蛋白质组分进行蛋白质免疫印迹分析发现，不仅这种受体——“Ck”普遍存在于各种人体器官中，尤其是肾上腺皮质、主动脉、肝脏和大脑，而且白血病细胞系以及慢性粒细胞白血病患者的淋巴细胞中该受体存在特异性和选择性缺陷。基于这些观察结果，我们提出白血病过程可能是由于这种新型受体——“Ck”的缺陷而引发的。
